PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score
(PROMIS Trial)
Recruiting in Palo Alto (17 mi)
+52 other locations
MT
Overseen byMichaela Tsai, MD
Age: 18+
Sex: Female
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Academic
Waitlist Available
Sponsor: Agendia
No Placebo Group
Trial Summary
What is the purpose of this trial?
This is a prospective study that will assess the impact of MammaPrint on chemotherapy + endocrine versus endocrine alone treatment decisions in patients with an Oncotype Intermediate Score.
Research Team
MT
Michaela Tsai, MD
Principal Investigator
Piper Breast Center
Eligibility Criteria
Inclusion Criteria
Women with histologically proven invasive stage I-II, node negative, hormone receptor positive, Her2 negative breast cancer, who received an Oncotype DX intermediate score (18-30)
≥ 18 years of age at time of consent
Written informed consent
Treatment Details
Interventions
- MammaPrint (Cancer Diagnostic Test)
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Subjects with MammaPrint ResultExperimental Treatment1 Intervention
Find a Clinic Near You
Who Is Running the Clinical Trial?
Agendia
Lead Sponsor
Trials
18
Recruited
44,100+